Leading injection moulder, Boddingtons, will exhibit at MTI EXPO together with its customer, advanced diagnostics company Cytosystems.
For the first time, the latter’s lifesaving medical device will be on show – a point of care collection device for fast and fail-safe testing/screening of cancer cells. Boddingtons has been involved in the design and development of this innovation from the outset.
Cytosystems is a new company, based in Aberdeen, Scotland, and specialising in advanced diagnostics systems for cancer detection.
The new device will be on show on the Boddingtons stand at the NEC, May 15-16 and is immediately available for licensing or purchasing. The simplicity and compactness of the device make for universal appeal. In theory, every GP surgery could benefit from its features.
The new product from Cytosystems has been some eighteen months in development with Boddingtons and is now set to move to full production. It is comprised of a number of moulded components in different polymers, opaque and clear, as well as sharps inside the product.
The full manufacturing skill set of Boddingtons has been utilised in putting the various device components together – technical moulding, welding, assembly, and deployment of medical needles have all been factored into production.
Boddingtons Managing Director, Andy Tibbs, says that ‘we are pleased and proud to next week be joined by our customer Cytosystems at MTI EXPO 2019. I urge all medical practitioners and healthcare specialists to visit our stand and take inspiration from what modern manufacturing methods can now achieve in the med-tech space.’
Since the launch of its £4.6m manufacturing facility in early 2017, Boddingtons has steadily expanded the scope and volume of its med-tech manufacturing services. The company is certified to ISO13485 and ISO9001 Quality Management Systems Requirements and is also compliant with FDA 21 CFR Part 820.
Expert Boddingtons personnel will be at hand throughout the MTI exhibition to give detail on the full scope of the company’s manufacturing services, including regulatory and quality assurance services.
Boddingtons is currently in the international MDSAP qualification for the medical industry – a commitment involving some £80,000 over the next three years, resulting in a medical product standard that has no frontiers and is completely universal.